Oasis Licenses Technology for Alzheimer's, Parkinson's POC Test | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Oasis Diagnostics today announced it has licensed technology from two researchers for the development of saliva-based point-of-care diagnostics for Alzheimer's and Parkinson's diseases.

Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.